Enveric Biosciences, Inc.

Enveric Biosciences is leveraging its discovery engine and intellectual property portfolio to identify and build the next generation of psychedelic and cannabinoid medicines for the mind and body. By harnessing the power of synthetic biology and chemistry, the company is optimizing what nature created to improve the human condition. Enveric is developing new and improved medicines to treat physical and mental ailments stemming from cancer and other conditions. Our mission is to improve the characteristics of psychedelic- and cannabinoid-derived pharmaceuticals by unlocking their full potential to create treatment solutions for a variety of indications with serious unmet medical needs. Enveric has created a robust, psychedelics-informed, IP portfolio, called The Psybrary™, along with a host of cannabinoid assets, through its unique discovery and development platform and collaborations with renowned global institutions.